InvestorRelations
Please contact us for any investor information using the form below.
CurrentNews
EmpowerPharm Inc. is delighted to announce the outcome of their Phase 2 clinical trial assessing Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD)
EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol ...
Read More →
EMPOWERPHARM AWAITS PHASE II CLINICAL TRIAL ON GROUND BREAKING TREATMENT TO MANAGE SOCIAL ANXIETY DISORDER
Burlington, ON March 11, 2024 - EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II clinical ...
Read More →
EmpowerPharm Patent- PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF CANNABINOIDS was published today.
EmpowerPharm® a clinical stage pharmaceutical company specializing in cannabinoid-based drug development of prescription products. These products target therapeutic indications where ...
Read More →